Immunologic systemic effect of neoadjuvant chemotherapy requires investigation before tumor-associated lymphocytes can be introduced in breast cancer treatment algorithm

Journal of Clinical Oncology

Volumn 28, Issue 27, 2010, Pages

  Bellati, Filippo ^a   Napoletano, Chiara ^a   Gasparri, Maria Luisa ^a   Panici, Pierluigi Benedetti ^a   Nuti, Marianna ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; PACLITAXEL; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXOID;

ADAPTIVE IMMUNITY; ALGORITHM; BREAST CANCER; CANCER ADJUVANT THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLORECTAL CANCER; DRUG EFFECT; HUMAN; IMMUNE SYSTEM; LETTER; LUNG CANCER; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; OVARY CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; IMMUNOLOGY; NOTE; PATHOLOGY; PATIENT SELECTION; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ALGORITHMS; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOADJUVANT THERAPY; PATIENT SELECTION; TAXOIDS; TREATMENT OUTCOME;

EID: 77957942202     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.27.9984     Document Type: Letter

References (23)

1. Denkert C, Loibl S, Noske A, et al: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105-113, 2010
2. Zhang L, Conejo-Garcia JR, Katsaros D, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203-213, 2003 (Pubitemid 36077915)
3. Galon J, Costes A, Sanchez-Cabo F, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964, 2006
4. Eerola AK, Soini Y, Pääkkö P: A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res 6:1875-1881, 2000
5. Zitvogel L, Apetoh L, Ghiringhelli F, et al: Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59-73, 2008
6. Tsuda N, Chang DZ, Mine T, et al: Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells. Cancer Res 67:8378-8387, 2007 (Pubitemid 47395177)
7. Vicari AP, Luu R, Zhang N, et al: Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 58:615-628, 2009
8. Casares N, Pequignot MO, Tesniere A, et al: Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202:1691-1701, 2005 (Pubitemid 41815875)
9. Demaria S, Volm MD, Shapiro RL, et al: Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 7:3025-3030, 2001 (Pubitemid 32963819)
10. Ladoire S, Arnould L, Apetoh L, et al: Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 14:2413-2420, 2008 (Pubitemid 351551075)
11. Carson WE 3rd, Shapiro CL, Crespin TR, et al: Cellular immunity in breast cancer patients completing taxane treatment. Clin Cancer Res 10:3401-3409, 2004 (Pubitemid 38685446)
12. Rehermann B, Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5:215-229, 2005 (Pubitemid 40364823)
13. Pantaleo G, Demarest JF, Soudeyns H, et al: Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature 370:463-467, 1994 (Pubitemid 24263551)
14. Letvin NL, Walker BD: Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med 9:861-866, 2003 (Pubitemid 36889927)
15. Klein L, Trautman L, Psarras S, et al: Visualizing the course of antigenspecific CD8 and CD4 T cell responses to a growing tumor. Eur J Immunol 33:806-814, 2003 (Pubitemid 36367684)
16. Griffith TS, Kazama H, VanOosten RL, et al: Apoptotic cells induce tolerance by generating helpless CD8+ T cells that produce TRAIL. J Immunol 178:2679-2687, 2007 (Pubitemid 46333144)
17. Green DR, Ferguson T, Zitvogel L, et al: Immunogenic and tolerogenic cell death. Nat Rev Immunol 9:353-363, 2009
18. Napoletano C, Bellati F, Landi R, et al: Ovarian cancer cytoreduction induces changes in t cell population subsets reducing immunosuppression. J Cell Mol Med [epub ahead of print on September 24, 2009]
19. Fisher B, Anderson S, Bryant J, et al: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233-1241, 2002 (Pubitemid 35176242)
20. Disis ML, Wallace DR, Gooley TA, et al: Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 27:4685-4692, 2009
21. von Minckwitz G, du Bois A, Schmidt M, et al: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A german breast group 26/breast international group 03-05 study. J Clin Oncol 27:1999-2006, 2009
22. Rastogi P, Anderson SJ, Bear HD, et al: Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778-785, 2008 (Pubitemid 351264391)
23. Ménard S, Tomasic G, Casalini P, et al: Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 3:817-819, 1997 (Pubitemid 27244351)